Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
US10016372B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 26, 2017 |
| Grant date | Jul 10, 2018 |
| Priority date | — |
| Expiry date | Jul 26, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.